FY2026 Earnings Forecast for MetaVia Issued By HC Wainwright

MetaVia Inc. (NASDAQ:MTVA – Free Report) – HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of MetaVia in a note issued to investors on Tuesday, November 17th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings of ($3.07) per share for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for MetaVia’s Q4 2026 earnings at ($0.72) EPS, FY2027 earnings at ($3.77) EPS, FY2028 earnings at ($2.28) EPS, FY2029 earnings at ($1.88) EPS and FY2030 earnings at ($1.58) EPS.

MetaVia (NASDAQ:MTVA – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a report on Monday, October 19th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, MetaVia has a consensus rating of “Hold” and an average target price of $20.00.

View Our Latest Research Report on MTVA

MetaVia Price Performance

MetaVia stock opened at $1.01 on Thursday. The business’s fifty day moving average is $1.40 and its two-hundred day moving average is $1.58. MetaVia has a 52 week low of $0.97 and a 52 week high of $13.42.

About MetaVia

(Get Free Report)

MetaVia, Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, including obesity, metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. The company’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being studied for obesity, and DA-1241, an investigational GPR119 agonist being developed for MASH and type 2 diabetes. These candidates are experimental and have not been established as approved treatments.

Featured Articles

Earnings History and Estimates for MetaVia (NASDAQ:MTVA)

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.